KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Shares Outstanding (Weighted Average) data on record, last reported at $255.7 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 0.85% year-over-year to $255.7 million; the TTM value through Dec 2025 reached $255.7 million, down 0.85%, while the annual FY2025 figure was $255.7 million, 0.85% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $255.7 million in Q4 2025 per VRTX's latest filing, roughly flat from $256.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $259.4 million in Q1 2021 and bottomed at $255.1 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $257.3 million, with a median of $257.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): fell 1.66% in 2022, then grew 0.9% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $257.7 million in 2021, then decreased by 0.62% to $256.1 million in 2022, then grew by 0.62% to $257.7 million in 2023, then grew by 0.08% to $257.9 million in 2024, then decreased by 0.85% to $255.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $255.7 million in Q4 2025, $256.4 million in Q3 2025, and $256.8 million in Q2 2025.